Author | Lightnews

BioPharmCatalyst @biopharmcatalyst.bsky.social · 7h

$ARMP's IV phage therapy for S. aureus showed 88% response vs 58% placebo in Phase 2a, supporting Phase 3 move. First randomized data for IV phage in SAB. #biotech

www.biopharmcatalyst.com/news/2025/ar...

Daily Updates 10/22/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 15h

$ARCT up on positive Phase 2 data for inhaled CF therapy—safe, early signs of benefit. 12-week study in 2026 planned. $ARCT $ALEC $BNBX $NRIX $TERN $OWLT $RANI $DRTS $SNOA $PCSA

www.biopharmcatalyst.com/news/2025/ar...

Pre-Market Updates 10/22/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 1d

$NERV gets $200M financing ($80M upfront) for Phase 3 roluperidone trial in schizophrenia; FDA approved design. Board expansion aims to boost execution.

www.biopharmcatalyst.com/news/2025/mi...

Daily Updates 10/21/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 1d

$IBIO to present new data at ObesityWeek/PEGS Europe on IBIO-610 for obesity, highlighting fat-selective weight loss and synergy with GLP-1s.

www.biopharmcatalyst.com/news/2025/ib...

Pre-Market Updates 10/21/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 2d

$ANRO announced a successful FDA meeting supporting accelerated development of ALTO-207 for treatment-resistant depression, with a $50 million private placement expected to fund a Phase 3 trial launch by early 2027.

See More Biotech Updates👇
www.biopharmcatalyst.com/news/2025/re...

BioPharmCatalyst @biopharmcatalyst.bsky.social · 2d

$KZR downgraded to Hold at Jefferies, PT cut to $7 (from $18) after Phase 3 FDA setback for zetomipzomib; company exploring options, future now uncertain.

www.biopharmcatalyst.com/news/2025/re...

Daily Updates 10/20/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 2d

$REPL up as FDA accepts RP1 BLA resubmission for advanced melanoma; PDUFA date set for April 10, 2026.

www.biopharmcatalyst.com/news/2025/re...

Pre-Market Updates 10/20/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 5d

$KZR downgraded to Hold by Jefferies, PT cut to $7 after FDA setback on zetomipzomib. Kezar now exploring strategic options, adding uncertainty.

www.biopharmcatalyst.com/news/2025/ar...

Daily Updates 10/17/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 5d

BioPharmCatalyst Watchlist: Top biotech stocks to watch—key Phase 1/2 catalysts in the next 6 months. $COGT $RZLT $DVBT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM www.biopharmcatalyst.com/news/2025/bi...

1

BioPharmCatalyst @biopharmcatalyst.bsky.social · 5d

$RANI inks $1.085B Chugai deal, gets $10M upfront plus milestones. With $60.3M raise, now funded into 2028 to advance oral biologics. $ARTV $XRTX $KZR $ACHV $PLX $AKAN $IRON $RCEL $NIVF

www.biopharmcatalyst.com/news/2025/ra...

Pre-Market Updates 10/17/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 6d

$TOVX raises $4M via warrant inducement; investors get new 5-year warrants at $0.54 pending approval. #biotech

www.biopharmcatalyst.com/news/2025/pr...

Daily Updates 10/16/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 6d

$PRAX reports positive Phase 3 results for ulixacaltamide in essential tremor, showing improved tremor control and daily function. #PremarketMovers

www.biopharmcatalyst.com/news/2025/pr...

Pre-Market Updates 10/16/25

export-download.canva.com

1

BioPharmCatalyst @biopharmcatalyst.bsky.social · 7d

$OMER sells OMS906 rights to Novo Nordisk for $340M upfront, total deal up to $2.1B plus royalties. Novo gets full control for rare blood and kidney disorder treatments.

www.biopharmcatalyst.com/news/2025/ge...

Daily Updates 10/15/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 7d

$GNPX: Reqorsa shows strong preclinical efficacy in ALK-EML4+ NSCLC; data to be presented at AACR-NCI-EORTC. Supports use with ALK inhibitors.

www.biopharmcatalyst.com/news/2025/ge...

Pre-Market Updates 10/15/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 8d

$GNPX’s Reqorsa shows strong preclinical results in ALK-EML4+ NSCLC models. More biotech news: $ATXS $NDRA $RCKT $GDTC $SBFM $EVAX $SNTI $CERO $IVVD.

www.biopharmcatalyst.com/news/2025/as...

Daily Updates 10/14/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 8d

$BCRX to acquire $ATXS for $13/share in cash & stock, valuing $ATXS at ~$700M. Deal expands BioCryst’s immunology portfolio. #PremarketMovers

www.biopharmcatalyst.com/news/2025/bi...

Pre-Market Updates 10/14/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 9d

$NDRA raises $4.9M via private placement to fund Arca-backed DeFi treasury, shifting focus toward blockchain assets while maintaining imaging tech.

www.biopharmcatalyst.com/news/2025/tv...

Daily Updates 10/13/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 9d

$TVRD drops after Phase 2 trial for TTI-101 in IPF misses goals; no FVC benefit, more GI side effects. Focus shifts to TTI-109, HCC trial ongoing.

www.biopharmcatalyst.com/news/2025/tv...

Pre-Market Updates 10/13/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 11d

BioPharmCatalyst Weekly #Watchlist

BioPharmCatalyst Weekly Watchlist: Key PDUFA and regulatory catalysts for the next 6 months

$COGT $RZLT $DBVT $BLTE $MBRX $IMVT $PCVX $BCTX $KALV $CGEM

biopharmcatalyst.com/news/2025/bi...

Biotech catalyst calendars and drug pipelines • BioPharmCatalyst

Profit on the stock market by investing in biotech stocks

biopharmcatalyst.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 12d

$QNRX inks deal with healthcare investors: raises $16.5M upfront, up to $104.5M total with warrants. #BiotechUpdates

www.biopharmcatalyst.com/news/2025/qu...

Daily Updates 10/10/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 12d

$SHPH to acquire Molecule.ai for $10M, boosting AI-driven drug discovery and streamlining therapeutic development. $SHPH $CARM $ARAY $CDT $ATYR $CDTX $ADTX $LITS $IVA $KIDS

www.biopharmcatalyst.com/news/2025/ca...

Pre-Market Updates 10/10/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 13d

$BJDX expands SanyoSeiko partnership for rapid sepsis test (IL-6, 20min), awaits FDA nod. Announces $2M private placement; new warrants exercisable at $1.75. $BJDX #biotech

www.biopharmcatalyst.com/news/2025/bl...

Daily Updates 10/09/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 13d

$CDT plans 1-for-8 reverse split to boost capital-raising, per board approval and May 2025 shareholder OK.

www.biopharmcatalyst.com/news/2025/bl...

Pre-Market Updates 10/09/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 14d

$NXL’s Gen-2 DIFS device showed significant cognitive gains in mild Alzheimer’s, offering strong peer-reviewed evidence for its non-invasive neuromodulation tech.

www.biopharmcatalyst.com/news/2025/ne...

Daily Updates 10/08/25

export-download.canva.com

BioPharmCatalyst @biopharmcatalyst.bsky.social · 14d

$SPRB raises $50M to advance tralesinidase alfa for MPS IIIB, aiming for BLA in Q1 2026 and potential US launch by late 2026.

www.biopharmcatalyst.com/news/2025/es...

Pre-Market Updates 10/08/25

export-download.canva.com